Our preclinical data suggest that targeted Sirt1 agonism represents a promising therapeutic intervention for progressive crystallopathic nephropathy, potentially disrupting the inflammation–crystallisation vicious cycle. The gene discussed is SIRT1; the disease is kidney disorder.